Direct Lytic Agents News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Direct lytic agents. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Direct Lytic Agents Today - Breaking & Trending Today

ContraFect to Present at the World Anti-Microbial Resistance Congress 2023

ContraFect to Present at the World Anti-Microbial Resistance Congress 2023
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United States , Michael Messinger , Garrett Nichols , Microbial Resistance Congress , Contrafect Corporation Nasdaq , Contrafect Corporation , Exchange Commission , World Anti Microbial Resistance Congress , Fect Corporation , Interim Chief Medical Officer , World Anti Microbial , Coagulase Negative Staphylococci , Direct Lytic Agents , Quarterly Report , Relations Contacts ,

ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit

ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit
YONKERS, N.Y., April 15, 2021 (GLOBE NEWSWIRE) ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Cara Cassino, MD, Chief Medical Officer and Executive Vice President of Research, will virtually present the Company’s anti-infective portfolio and platform technology of DLAs in the session on “Advancing Clinical Superiority of Anti-Infectives to Drive Commercial Success.”
Dr. Cassino’s presentation will focus on the powerful antimicrobial attributes of DLAs which underpin the potential for superior clinical outcomes for serious, life-threatening, and critically underserved infections and the Company’s novel development pa ....

Cara Cassino , Carlo Tanzi , Michael Messinger , Exchange Commission , Contrafect Corporation Nasdaq , Contrafect Corporation , Chief Medical Officer , Executive Vice President , Clinical Superiority , Drive Commercial Success , Direct Lytic Agents , New Medical Modalities , Discussion Follows , Breakthrough Therapy , காரா கேசினோ , கார்லோ டான்சி , மைக்கேல் மெசிங்கர் , பரிமாற்றம் தரகு , தலைமை மருத்துவ அதிகாரி , நிர்வாகி துணை ப்ரெஸிடெஂட் , திருப்புமுனை சிகிச்சை ,